US Stock MarketDetailed Quotes

INDP Indaptus Therapeutics

Watchlist

2.490
+0.050+2.05%

Close Apr 23 16:00 ET

21.26MMarket Cap-1360P/E (TTM)

Indaptus Therapeutics Stock Forum

Stock Region

Apr 12 23:27

$PXMD - PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission

Indaptus Therapeutics: A Beacon of Hope in Cancer Treatment Unveiled at AACR Meeting.
In a groundbreaking presentation at the American Association for Cancer Research (AACR) Annual Meeting, Indaptus Therapeutics Inc. (NASDAQ: INDP) has shared promising data that could potentially revolutionize the way we approach cancer treatment. Their research focuses on the Decoy bacteria tech...

Trytosaveabit

Apr 11 19:37

Update

$Indaptus Therapeutics(INDP.US)$ Indaptus Therapeutics Unveils Details On Mechanism Of Action Data That Demonstrates The Company's Decoy Platform Induces, Matures Or Activates Multiple Immune Cell Types Involved In Anti-tumor Responses, At AACR Research Annual Meeting

Stock Region

Mar 5 07:25

Therapeutics Company Reports Positive Results For Cancer Therapy

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort.
Indaptus Therapeutics Inc. (NASDAQ: INDP), a pioneering biopharmaceutical company, has recently announced encouraging results from the second cohort of its Phase 1 clinical trial. This announcement marks a significant milestone in the company's relentless efforts to develop groundbreaking therapies for cancer pa...

Trytosaveabit

Mar 4 20:34

Update

$Indaptus Therapeutics(INDP.US)$ Indaptus Therapeutics Announces Results From Second Cohort Of Phase 1 Trial; Initiates Multi-Dose Cohort
Moomoo 24/7· 1 min ago
Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to recommend initiating multi-dosing cohort